

Title (en)
INHIBITION OF CYST FORMATION BY CYTOSKELETAL SPECIFIC DRUGS.

Title (de)
HEMMUNG DER BILDUNG VON ZYSTEN MITTELS ZYTOSKLETTSPEZIFISCHER ARZNEIMITTEL.

Title (fr)
INHIBITION DE LA FORMATION DE KYSTES A L'AIDE DE MEDICAMENTS SPECIFIQUES CYTOSQUELETTIQUES.

Publication
EP 0663958 A4 19991020 (EN)

Application
EP 93922390 A 19930924

Priority
• US 9309124 W 19930924
• US 95127092 A 19920925

Abstract (en)
[origin: WO9408041A1] The invention provides a method of treating a mammal having a cystic disease. This method includes identifying a mammal having a cystic disease, and administering to the identified mammal a pharmacologically effective anti-cystic amount of an agent that interferes with the normal functioning of a cytoskeletal component or one that inhibits delivery of membrane proteins to the membrane. The agent is administered in a pharmacologically acceptable carrier, excipient or diluent. The invention also includes an (in vitro) assay system and use of such a system to identify agents useful in the treatment of cystic diseases.

IPC 1-7
C12Q 1/02

IPC 8 full level
A61K 31/165 (2006.01); **A61K 31/335** (2006.01); **A61K 31/34** (2006.01); **A61K 31/365** (2006.01); **A61K 31/40** (2006.01); **A61K 31/415** (2006.01); **A61K 31/475** (2006.01); **A61K 38/08** (2019.01); **C12N 5/06** (2006.01); **C12N 5/071** (2010.01); **G01N 33/50** (2006.01)

CPC (source: EP US)
A61K 31/165 (2013.01 - EP); **A61K 31/335** (2013.01 - EP); **A61K 31/34** (2013.01 - EP); **A61K 31/365** (2013.01 - EP); **A61K 31/40** (2013.01 - EP); **A61K 31/415** (2013.01 - EP); **A61K 31/475** (2013.01 - EP); **A61K 38/08** (2013.01 - EP US); **C12N 5/0686** (2013.01 - EP); **G01N 33/5008** (2013.01 - EP); **C12N 2503/02** (2013.01 - EP); **G01N 2500/00** (2013.01 - EP)

Citation (search report)
• [XY] S. RUBINO ET AL.: "The cytoskeleton of hydatid cyst cultured cells and its sensitivity to inhibitors", EUR. J. CELL. BIOL., vol. 30, no. 2, 1983, pages 182 - 190, XP000616612
• [X] WOO, D.D.-L.: "Cytoskeletal specific drugs inhibit in-vitro cyst formation.", J. AM. SOC. NEPHROL., vol. 3, no. 3, September 1992 (1992-09-01), pages 304, XP002025249
• [X] Y. RAVIA: "Differences between cystic fibrosis and normal cells in the degree of satellite association", HUM. GENET., vol. 71, no. 4, December 1985 (1985-12-01), pages 294 - 300, XP000616611
• [X] G.L. FORREST: "Colchicine Binding activity and Tyrosyl tubulin ligase activity in normal and cystic fibrosis fibroblasts.", BIOCHEM. BIOPHYS. RES. COMM., vol. 98, no. 1, 15 January 1981 (1981-01-15), pages 324 - 329, XP000616636
• [XP] B. SIEGAL: "The polycystic kidney donor", TRANSPLANTATION, vol. 54, no. 6, December 1992 (1992-12-01), pages 1131, XP000616618
• [Y] BUDAVARI, S. ED.: "The Merck Index", 1989, MERCK & CO., INC., RAHWAY, N.Y., U.S.A., XP002025339
• [A] R. MANGOO-KARIM ET AL.: "RENAL EPITHELIAL CYST FORMATION AND ENLARGEMENT IN VITRO: DEPENDENCE ON cAMP.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, August 1989 (1989-08-01), WASHINGTON US, pages 6007 - 6011, XP002109991
• See references of WO 9408041A1

Designated contracting state (EPC)
DE ES FR GB IT

DOCDB simple family (publication)
WO 9408041 A1 19940414; AU 5140193 A 19940426; CA 2145680 A1 19940414; EP 0663958 A1 19950726; EP 0663958 A4 19991020

DOCDB simple family (application)
US 9309124 W 19930924; AU 5140193 A 19930924; CA 2145680 A 19930924; EP 93922390 A 19930924